Showing results (181-190 of 427) with videos related to
Sort By:
Pageof 43
The Oncologist|March 26, 2017
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast CancerAnthony F Yu, Jasmeet C Singh, Rui Wang, et al.Breast Cancer Research and Treatment|February 29, 2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)G G Kimmick, C Cirrincione, D B Duggan, et al.Plastic and Reconstructive Surgery|August 28, 2014
Diminishing relative contraindications for immediate breast reconstructionClaudia R Albornoz, Peter G Cordeiro, Gina Farias-Eisner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancerAman Buzdar, Joyce A O'Shaughnessy, Daniel J Booser, et al.Breast Cancer Research and Treatment|September 8, 2011
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancerDevika Gajria, Joseph Gonzalez, Kimberly Feigin, et al.Cancer|September 16, 2011
Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiationAlice Ho, Peter Cordeiro, Joseph Disa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancerJennifer J Griggs, Mark R Somerfield, Holly Anderson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrheaChau Dang, Nancy Lin, Beverly Moy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancerMonica N Fornier, Andrew D Seidman, Diana Lake, et al.Breast Cancer Research and Treatment|April 2, 2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi, Andrew D Seidman, Maura Dickler, et al.Pageof 43